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hould Percutaneous
evascularization for Stable
oronary Artery Disease Be
erformed Sooner or Later?*
bhiram Prasad, MD, FRCP, FESC, FACC,
ernard J. Gersh, MBCHB, DPHIL, FACC
ochester, Minnesota
oronary artery disease (CAD) represents a spectrum that
aries in severity from single- to triple-vessel disease with
linical presentation ranging from stable angina to an acute
oronary syndrome (ACS) or sudden cardiac death. Man-
gement of the condition has evolved significantly during
he last 3 decades as a consequence of the advances in
edical therapy, a pivotal component of which is aggressive
isk factor reduction, percutaneous coronary intervention
PCI), and cardiac surgery. Data from multiple clinical trials
ndicate that treatment, including the use of revasculariza-
ion, needs to be individualized for each patient depending
n the coronary anatomy, ischemic burden, left ventricular
unction, and the overall clinical milieu, including the
mpact of symptoms upon quality of life and the presence
nd severity of comorbidities. General agreement exists that
CI is beneficial, and the preferred strategy, in high-risk
atients (ST-segment elevation myocardial infarction and
igher-risk non–ST-segment elevation acute coronary syn-
See page 469
romes) in whom it reduces morbidity and mortality (1,2).
he role of PCI in lower-risk patients such as those with
table CAD is different and predominantly directed at the
elief of symptoms and ischemia. The publication of the
OURAGE (Clinical Outcomes Utilizing Revasculariza-
ion and Aggressive Drug Evaluation) trial has rekindled the
ebate over the relative merits of medical therapy versus
CI for stable CAD (3).
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.
From the Division of Cardiovascular Diseases and Department of Internal
edicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota. Dr. Gersh iss
member of Advisory Boards for CV Therapeutics, Boston Scientific, and Abbott
aboratories.In this issue of the Journal, Nishigaki et al. (4) present
ata from the latest randomized trial to compare medical
herapy with PCI in patients with stable CAD. The study is
nique in that it was conducted among a non-Western
opulation of 384 patients recruited from 78 centers in
apan. The choice of antianginal and secondary preventive
herapies in both arms was at the discretion of the physi-
ians and not mandated by the protocol. Thus, medical
herapy in this trial reflected “real-world” practice as op-
osed to the case-management approach used in the opti-
al medical therapy strategy of the COURAGE trial (3).
nclusion criteria were the presence of a significant stenosis
ocumented on a coronary angiogram in addition to either
history of angina or electrocardiographic evidence of
schemia. Those patients enrolled represented an exceed-
ngly low-risk population with approximately two-thirds
xhibiting single-vessel disease and none exhibiting triple-
essel disease.
Patients with a reduced ejection fraction, chronic total
cclusions, vein graft lesions, and significant comorbid
onditions including creatinine greater than 1.5 g/dl were
xcluded. This is reflected in the very low annual mortality
ate of1% (compared with4% in the COURAGE trial)
3) and the fact that 90% of patients had either no or
ild angina. Stent use (76%) was lower, whereas the use
f balloon angioplasty alone (15%) and atherectomy was
reater than one might expect in contemporary practice in
he U.S.
he PCI-related reduction in acute coronary syndromes. The
tudy was terminated prematurely after an interim analysis
emonstrating reduced events in the PCI arm, although the
omposite end point used had not been selected a priori. As
bserved in previous randomized trials, there was no differ-
nce in the primary end point of all-cause mortality in the 2
roups, although the study was vastly underpowered to
etect a reduction in death. It was found that PCI was
ssociated with lower frequency of the primary end points of
CS (11.7% vs. 5.0%, p  0.012) and emergency
ospitalization.
Although it is generally accepted that PCI reduces
ecurrent ACS in patients with unstable disease, this finding
as not been a consistent one in patients with stable CAD.
hus, the observed reduction in ACS with percutaneous
evascularization in the study by Nishigaki et al. (4) is of
nterest. There are several important factors that must to be
onsidered in interpreting their data. First, the reduction in
he rate of ACS was exclusively due to the reduction in
nstable angina (8.9% vs. 3.4%, p  0.028) rather than
yocardial infarction (3.8% vs. 1.6%, p  0.20). Unstable
ngina was defined as “emergency admission for ischemic
ardiac pain associated with electrocardiographic signs of
yocardial ischemia and coronary stenosis of 90%” in the
bsence of a myocardial infarction. Despite the attempts to





































































































J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 1 , N O . 5 , 2 0 0 8
O C T O B E R 2 0 0 8 : 4 8 0 – 2
Prasad and Gersh
Editorial Comment
481ngina is a subjective diagnosis and a weak end point for a
linical trial.
Second, the authors state that it is routine practice in
apan to perform coronary angiography 3 to 12 months after
CI. Follow-up angiography also was recommended within
to 2 years in the medically treated patients by the protocol.
hus, there is the distinct possibility that knowledge of the
ngiographic findings by the participants and physicians,
ho were not blinded, may have been a source of bias.
hird, data regarding periprocedural myocardial infarction
ere not provided and, therefore, one cannot assess whether
ncorporating clinically significant events at the time of the
CI might have reduced the net benefit from PCI.
Fourth, the frequency of smokers, who are at greater risk
or ACS, was 2-fold greater in the medical arm. Finally,
here was suboptimal therapy of hyperlipidemia in both
roups, with a mean low-density lipoprotein of 106 mg/dl at
years with a trend toward less statin use in the medical arm
55.9% vs. 65.4%, p  0.14). Thus, PCI appeared to reduce
he rate of unstable angina, an observation that may have
esulted from systematic bias, as well as differences between
he groups with regard to baseline characteristics and
edical therapy.
However, the reduction in unstable angina by PCI may
ave been due to better relief of ischemia. Indeed, the
ndings are consistent with those reported in the TIME
Trial of Invasive versus Medical therapy in Elderly pa-
ients) study (5), in which continued medical management
lone was associated with an approximate 50% probability
f hospitalization and revascularization over the subsequent
year. Patients enrolled in that study were more symptom-
tic and at much greater risk with almost a 10-fold greater
nnual mortality.
se of PCI and symptom relief. The second RITA (Ran-
omized Intervention Treatment of Angina-2) trial was
mong the earliest studies to demonstrate that PCI is more
ffective than medical therapy in relieving angina, a finding
hat has been replicated in subsequent studies (6). Nishigaki
t al. (4) once again report this benefit of PCI in the stent
ra. Although the reduction in the severity of angina was
odest, it was apparent immediately after revascularization
nd persisted for the entire duration of follow-up (median
.3 years). This reduction was accompanied by a reduction
n the need for nitrate therapy. The results are consistent
ith the data from the COURAGE trial in which an initial
CI strategy was superior to optimal medical therapy alone
ith regard to quality of life and symptom control, though
he benefit diminished over time (7). It is worth noting that
he benefit of PCI, with regard to the relief of ischemia, may
ave been underestimated due to the fact that 36.5% of
atients in the medical arm crossed over to elective
evascularization.
se of PCI and ischemic burden. The efficacy of PCI in
elieving ischemia and the potential for improving outcomes in selected patients with stable CAD is supported by a
ubstudy of the COURAGE trial among 314 patients who
ad documented ischemia at baseline on myocardial perfu-
ion stress testing and underwent repeat assessment at 6 to
8 months after assignment to treatment (8). The patients
n the PCI and optimal medical therapy groups were well
atched in terms of severity of angina, severity of CAD,
nd ejection fraction. Patients in the PCI arm were far more
ikely (33.3% vs. 19.8%, p  0.004) to have a reduction in
schemic burden of5% of the myocardium compared with
hose patients treated with optimal medical therapy alone.
mportantly, patients in whom there was a reduction in
schemic burden had lower rates of death or myocardial
nfarction. This benefit was greatest in patients who had
oderate to severe ischemia at baseline. There was no death
r myocardial infarction in patients who had no residual
schemia at follow-up, compared with a rate of 39.3%
mong those who had 10% of the myocardium with
esidual ischemia.
These data suggest that PCI relieves angina to a greater
xtent and that less residual ischemia is associated with
etter outcomes. Nonetheless, although this is an interest-
ng substudy, it should be emphasized that in the overall
OURAGE trial there was no reduction in death or
yocardial infarction with PCI. Treatment strategies based
n relieving ischemic burden have not been formally tested
n stable CAD and should be considered in the design of
uture trials.
onclusions
he use of PCI is very effective and superior to medical
herapy for reducing or abolishing angina and improving
unctional status. However, revascularization must be con-
idered an adjunct, rather than an alternative, to optimal
edical therapy. An initial medical strategy is suitable for
any patients, though at least one-third will cross over to
evascularization. Thus, sooner or later, PCI is required for
significant proportion of patients, regardless of the initial
trategy. Nonetheless, the major lessons of almost 3 decades
f trials of revascularization versus medical therapy in
atients with chronic stable angina and preserved left
entricular systolic function need to be reinforced. There is
o difference in the “hard” end points of death and myo-
ardial infarction with either strategy. The high incidence of
rossover from medical therapy to revascularization is not a
imitation of the trials but represents the realities of clinical
ractice.
However, what is reassuring is that the price to be paid
or revascularization “later rather than sooner” is not that of
eath or myocardial infarction. These trials help us as
linicians to make a rational choice for the individual
atient. There are no lack of data—the onus is on us to
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482xtrapolate the data from the recent trials to patients with
table CAD who have not had angiography or those with
evere symptoms as they were not included. Issues that need
o be evaluated in future research include the impact of
rug-eluting stents on the durability of the benefit from
CI, developing strategies based on ischemic burden and
omplete revascularization to maximize the potential benefit
f PCI on outcomes, and further assessing the impact of
mproved approaches to secondary prevention.
eprint requests and correspondence: Dr. Bernard J. Gersh,
ayo Clinic, 200 First Street SW, Rochester, Minnesota 55905.
-mail: gersh.bernard@mayo.edu.
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